BELITE BIO, INC Logo

BELITE BIO, INC

Developing novel oral therapies for retinal degenerative eye diseases like GA and Stargardt disease.

BLTE | US

Overview

Corporate Details

ISIN(s):
US07782B1044
LEI:
Country:
United States of America
Address:
12750 HIGH BLUFF DRIVE SUITE 475, 92130 SAN DIEGO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Belite Bio, Inc. is a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics for retinal degenerative eye diseases with significant unmet medical needs. The company's primary targets include atrophic age-related macular degeneration (specifically Geographic Atrophy, or GA) and Stargardt disease (STGD1). Its therapeutic pipeline is built on a proprietary portfolio targeting Retinol Binding Protein 4 (RBP4). The lead candidate, Tinlarebant (LBS-008), is a novel oral therapy designed to reduce the accumulation of ocular toxins that contribute to disease progression. Tinlarebant is in late-stage development with multiple Phase 3 trials and has received numerous regulatory designations, including Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease designations in the U.S. and other key markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all BELITE BIO, INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BELITE BIO, INC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BELITE BIO, INC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Sarepta Therapeutics, Inc. Logo
Develops precision genetic medicines for rare neuromuscular disorders.
United States of America SRPT
Savara Inc Logo
Clinical-stage biopharma developing inhaled therapies for rare respiratory diseases.
United States of America SVRA
SAWAI GROUP HOLDINGS Co., Ltd. Logo
A leading Japanese generic drug maker expanding into digital health and wellness solutions.
Japan 4887
Scandion Oncology A/S Logo
Biotech company in liquidation, formerly developing therapies to overcome cancer drug resistance.
Denmark SCOL
Scholar Rock Holding Corp Logo
Biopharma developing medicines for neuromuscular diseases by targeting protein growth factors.
United States of America SRRK
Scienture Holdings, Inc. Logo
Develops and commercializes specialty drugs for unmet medical needs, focusing on CNS disorders.
United States of America SCNX
Scilex Holding Co Logo
Develops and commercializes non-opioid products for acute and chronic pain management.
United States of America SCLX
Scinai Immunotherapeutics Ltd. Logo
Dual-model biopharma: developing NanoAbs for I&I and offering CDMO services.
United States of America SCNI
SciSparc Ltd. Logo
Developing cannabinoid-based therapies for central nervous system (CNS) disorders.
United States of America SPRC
Develops high-purity stem cell therapies for incurable immunological and inflammatory diseases.
South Korea 298060

Talk to a Data Expert

Have a question? We'll get back to you promptly.